P1.03-054 A Phase II Randomized Trial of Gefitinib Alone vs Olaparib Plus Gegitinib in Advanced NSCLC EGFRmut + Goal Trial Spanish Lung Cancer Group

导出原文传递

翻译打印收藏纠错

作者： B. Massuti ^[1] ; R. García Campelo ^[2] ; O. Arrieta ^[3] ; D. Rodríguez-Abreu ^[4] ; A.L. Ortega Granados ^[5] ; M. Majem ^[6] ; D. Vicente Baz ^[7] ; P. Lianes ^[8] ; J. Bosch Barrera ^[9] ; A. Insa ^[10] ; M. Domine ^[11] ; N. Reguart ^[12] ; M. Guirado ^[13] ; M. Sala ^[14] ; S. Vazquez ^[15] ; R. Bernabe ^[16] ; J.A. Macias ^[17] ; R. Palmero ^[18] ; A. Verdu ^[19] ; A. Drozdowskyj ^[20] ; R. Rosell ^[21]

作者单位： Hospital Clinico Valencia ^[1] Hospital Morales Meseguer ^[2] Hospital Mataro ^[3] Gecp ^[4] Hospital Universitario de Valme ^[5] Hospital Universitario Lucus Augusti ^[6] Hospital Basurto ^[7] Medical Oncology, Hospital Clinic ^[8] Medical Oncology, Complejo Hospitalario de Jaén ^[9] Hospital Teresa Herrera ^[10] Ico-H. Duran I Reynals ^[11] Catalan Institute of Oncology. Hospital Universitari Dr. Josep Trueta ^[12] Laboratory of Experimental Oncology and Thoracic Oncology Unit, National Cancer Institute ^[13] Medical Oncology, Hospital Virgen Macarena ^[14] Pivotal ^[15] Hopital de La Santa Creu I Sant Pau ^[16] Medical Oncology, Alicante University Hospital ^[17] Oncology, Hospital Universitario- Fundacion Jimenez Diaz ^[18] Medical Oncology, Hospital Universitavio Insular de Gran Canaria ^[19] Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias I Pujol ^[20] Hospital General de Elche ^[21]

发布时间 2019-09-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交